Lilly’s Global Obesity Surge | Durham News

Eli Lilly’s Q2 earnings shattered expectations and shifted investor focus from U.S. launch concerns to explosive international growth, especially in Europe, Japan, and China, where their GLP-1 drugs and upcoming oral pill Foundayo are poised to dominate. Bank of America raised its price target, citing faster-than-competitor growth and a massive 50% revenue surge, while Lilly confidently boosted its full-year forecast. With a deep R&D pipeline and global approvals already in place, the company is betting big on overseas markets to outpace domestic sales — and analysts are cheering them on. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/719f867c6ee9976a